Plain-English translation of NCT07152782 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing (a targeted cancer medication) given alone or combined with a second drug called , in women whose breast cancer has spread to the brain. The goal is to find out if adding the second medication helps control the cancer better than the first medication by itself, and whether it is safe to use together.
Breast cancer that spreads to the brain is very difficult to treat, and current options are limited. Researchers want to see if this medication combination can help more patients by working better against cancer cells in the brain while being tolerable to take.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the medication alone or the medication combined with a second pill taken by mouth. The primary medication is given as an intravenous infusion every three weeks. You will continue treatment until your cancer progresses outside the brain, or until side effects become too difficult to manage. Throughout the trial, you will have regular blood tests, imaging scans, and clinic visits to monitor how well the treatment is working and how you are tolerating it.
AI-generated summary from trial data · Oct 7, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fudan University
Enrollment target
~202 participants
Started
September 2025
Primary completion
August 2029
Age range
18 Years – 70 Years
Sex
Female only
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhimin Shao, Professor
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.